Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia
Janek S. Walker(The Ohio State University), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sameer A. Parikh(Mayo Clinic), Laura Z. Rassenti(University of California San Diego), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Hatice Gülçin Özer(Eli Lilly (United States)), Jordan Skinner(The Ohio State University), Casey B. Cempre(The Ohio State University), Katie Williams(The Ohio State University), Qingxiang Sun(University of Electronic Science and Technology of China), Thomas J. Kipps(University of California San Diego), J.M. Baumhardt(The University of Texas Southwestern Medical Center), Kerry A. Rogers(The Ohio State University), Christopher C. Oakes(The Ohio State University), Vincenzo Coppola(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Larry Beaver(The Ohio State University), Benjamin R. Stromberg(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Bonnie K. Harrington(Michigan State University), Sharon Shacham(Roche (Switzerland)), Matthew K. Summers(The Ohio State University), Yuh Min Chook(The University of Texas Southwestern Medical Center), Lynne V. Abruzzo(The University of Texas MD Anderson Cancer Center), Brian Giacopelli(The Ohio State University), Zachary A. Hing(The Ohio State University), John C. Byrd(University of Cincinnati), Amy Lehman(The Ohio State University Wexner Medical Center), Neil E. Kay(Mayo Clinic)
Cited by 55
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k